Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DS Espha to Launch Velcade Authorized Generic in December
August 24, 2021
- Bayer Yakuhin Names Julio Triana as New President
August 23, 2021
- HIF-PH Drug Evrenzo Gets European Nod: Astellas/FibroGen
August 23, 2021
- Ono’s Colorectal Cancer Drug Braftovi Approved in South Korea
August 23, 2021
- Shipments of 64 Choseido-Made Products Now Adjusted or Halted
August 20, 2021
- Sawai’s Shipment Curbs Now Affect 414 Products
August 20, 2021
- Sanwa Kagaku Rolls Out Upasita for Secondary Hyperparathyroidism
August 20, 2021
- Nihon Generic Lifts Shipment Curbs on Symbicort Generic
August 19, 2021
- MEI, Kyowa Begin PIII Study on Lymphoma Drug Zandelisib
August 19, 2021
- Rexulti Misses Mark in PII BPD Trial: Otsuka
August 19, 2021
- Yamasa Ramps Up API CMO Biz for Oligonucleotides, mRNA Drugs amid Changes in Modalities
August 19, 2021
- Wakamoto Grants North American Rights for MaQaid to Harrow
August 19, 2021
- Otsuka Wins Japan Approval for OD Tablet Form of Rexulti
August 19, 2021
- 1st Drug for Short Bowel Syndrome Now Available in Japan: Takeda
August 19, 2021
- Sawai to Suspend Shipments of Loperamide Capsules after Foreign Matter Identified
August 19, 2021
- Nichi-Iko, Medipal Form Capital Tie-Up; 5.2 Billion Yen Investment Goes towards CapEx
August 18, 2021
- MSD to Lift Shipment Restrictions on Pneumovax
August 18, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- Choseido Likely to Face Administrative Penalty over Manufacturing Flaws
August 18, 2021
- 1st Patient Dosed in Multinational PII Study of Brincidofovir: SymBio
August 18, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…